Comment(s)

Osiris Therapeutics, a publicly traded Maryland biotechnology company, won a $224.7 million contract from the Department of Defense to develop Prochymal, a drug that will treat military personnel exposed to radiation from nuclear or radiological attacks.  For more on this story, visit U.S. Deal Boosts Radiation Drug and return to comment below.

Up Next

US Military Officials: Iranian boats made ‘threatening’ moves toward U.S. Navy

Osiris Therapeutics, a publicly traded Maryland biotechnology company, won a $224.7 million contract from the…